Comparative drug screening in NUT midline carcinoma. - Wikidata - wikimedia - TriplyDB

Comparative drug screening in NUT midline carcinoma.

Comparative drug screening in NUT midline carcinoma.

http://www.wikidata.org/entity/Q37632187

about

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery The Oncoprotein BRD4-NUT Generates Aberrant Histone Modification Patterns Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.NUT carcinoma in children and adults: A multicenter retrospective study.CDK9: A key player in Cancer and Other Diseases.Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma.Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma.Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.

P2860

Q28260105-40B7CB98-F042-4CE3-9E61-A3BDC728DCDE Q36152206-0D16A79D-BEB6-427A-A4B5-89F0A28F4D03 Q37269236-95442691-11C2-4638-9E7F-48C238FA6A98 Q39393379-EED3C4FD-D342-47B0-862D-8D046E1E10D2 Q40117228-C513B59B-1AE0-4627-A8BC-E8D2902DE454 Q41098457-1DDAF899-3F4E-4F72-8005-3D7E8B7FA55C Q43142204-8CD58A01-7A98-46D9-BC3C-07DCD9C4D89E Q45141257-634EF99A-40D6-4BFE-99D2-C56C4590A771 Q47119688-A1C85B9F-566F-4756-AFC4-63ABCD02986D Q49166169-F56C6CA4-3816-4878-9C8E-8C7CDF31F32E

P2860

Comparative drug screening in NUT midline carcinoma.

http://www.wikidata.org/entity/Q37632187

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Comparative drug screening in NUT midline carcinoma.

@en

Comparative drug screening in NUT midline carcinoma.

@nl

type

label

Comparative drug screening in NUT midline carcinoma.

@en

Comparative drug screening in NUT midline carcinoma.

@nl

prefLabel

Comparative drug screening in NUT midline carcinoma.

@en

Comparative drug screening in NUT midline carcinoma.

@nl

P1433

Q37632187-09DF76F5-2421-46B2-8570-387787E2E2DE

P1476

Q37632187-200A9762-B39C-48E2-8FEA-9165F7D0EDBC

P2093

Q37632187-5F629921-21D2-46F4-BFF3-A1D4D2EEC51D

Q37632187-67E47BAC-BDE8-4CD5-9750-966BD11516E7

Q37632187-AF0BF04F-EB9F-4BA2-907B-B93D53E7EE1B

Q37632187-B70F9A5B-321E-4632-8739-614FDDDE6989

Q37632187-C2FD7975-1365-4DA8-9935-730AB0507664

Q37632187-E6A85F32-C59F-4175-8674-C85E7A50ED36

Q37632187-FF501D9D-841B-4A79-8C6A-5C03852E54E9

P2860

Q37632187-035CA350-7EDB-401C-A095-7E459C3D7D18

Q37632187-060BA2DE-9C60-40EE-A420-D90B5E3ACE86

Q37632187-12F16168-FE26-4999-8794-2C6BC39E5117

Q37632187-1C29A3CD-39D7-4AA9-899A-C1EC3948899E

Q37632187-1C8E8FBD-388D-4F26-B731-06787088D370

Q37632187-21732A6A-1702-4093-A53D-736D5638144D

Q37632187-231FB2DF-ECF5-4EC1-BF48-1CD3229C7816

Q37632187-2405B784-DB52-4323-8790-7E1AF05E2A8E

Q37632187-2762BC41-27B6-4ADD-9D9D-16DBBF565462

Q37632187-28D2CD66-4771-48D4-98E8-5378ACCA7646

P2888

Q37632187-E8ACBDE5-3811-43DB-9878-C725992BEB21

P304

Q37632187-6C158046-948F-47D9-B2F2-D6D3CDC3F294

P31

Q37632187-0973E7AF-808A-4244-92E0-DE4A488B0F4F

P356

Q37632187-8F042DA1-804F-41C3-A7C3-AB3490C14231

P407

Q37632187-6A7505DA-D8A7-4F2E-80EE-50A16A145DF8

P433

Q37632187-C71C4DAC-0524-4463-8695-E3BFFF27D38A

P478

Q37632187-F4515FC5-5336-4494-A2EB-078B0D66E1E3

P50

Q37632187-664A693A-13B2-4E0E-AB37-614A39A73F1F

Q37632187-6B27E0E5-D8A0-4C7A-976B-242CBCC1A31E

Q37632187-F0D7B68B-802A-428B-B1EA-EFAE5D55E5A5

P577

Q37632187-D4CC2DB5-A00C-4BA0-82FF-1D7B134FE374

P5875

Q37632187-81D5D9F4-1118-4F55-A480-065294A20695

P698

Q37632187-EE986014-42E7-451E-9BB8-901DD1325EC2

P921

Q37632187-21B080A6-D6F7-4EEB-A6CA-0ED4875F226D

P932

Q37632187-8FDD2CF9-3B87-4821-B797-07ABB8F3825E

P356

P1433

British Journal of Cancer

P1476

Comparative drug screening in NUT midline carcinoma.

@en

P2093

A Stirnweiss

http://www.w3.org/2001/XMLSchema#string

C H Cole

http://www.w3.org/2001/XMLSchema#string

E Ferrari

http://www.w3.org/2001/XMLSchema#string

G M Arndt

http://www.w3.org/2001/XMLSchema#string

M Howlett

http://www.w3.org/2001/XMLSchema#string

T W Failes

http://www.w3.org/2001/XMLSchema#string

U R Kees

http://www.w3.org/2001/XMLSchema#string

P2860

The bromodomain protein Brd4 insulates chromatin from DNA damage signalling

Selective inhibition of BET bromodomains

Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

BET domain co-regulators in obesity, inflammation and cancer

Demystified molecular pathology of NUT midline carcinomas

Activation of JNK triggers release of Brd4 from mitotic chromosomes and mediates protection from drug-induced mitotic stress

P2888

P304

1189-1198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.54

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Adrian K. Charles

Alex H. Beesley

Raelene Endersby

P577

2014-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260148880

http://www.w3.org/2001/XMLSchema#string

P698

24518598

http://www.w3.org/2001/XMLSchema#string

P921

P932

3950881

http://www.w3.org/2001/XMLSchema#string